Market closed
Verve Therapeutics/$VERV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Verve Therapeutics
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
Ticker
$VERV
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
274
Website
VERV Metrics
BasicAdvanced
$485M
-
-$2.35
1.78
-
Price and volume
Market cap
$485M
Beta
1.78
52-week high
$9.31
52-week low
$2.86
Average daily volume
4.1M
Financial strength
Current ratio
12.649
Quick ratio
12.294
Long term debt to equity
12.067
Total debt to equity
14.184
Management effectiveness
Return on assets (TTM)
-20.41%
Return on equity (TTM)
-36.36%
Valuation
Price to revenue (TTM)
14.307
Price to book
0.98
Price to tangible book (TTM)
0.98
Price to free cash flow (TTM)
-2.866
Growth
Revenue change (TTM)
174.98%
Earnings per share change (TTM)
-24.77%
3-year earnings per share growth (CAGR)
-19.39%
What the Analysts think about VERV
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Verve Therapeutics stock.
VERV Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
VERV Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
VERV News
AllArticlesVideos
Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy'
Seeking Alpha·2 weeks ago
Verve Therapeutics Touts Positive Data From Gene Editing Medicine To Lower Cholesterol After Single Dose
Benzinga·2 weeks ago
Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Verve Therapeutics stock?
Verve Therapeutics (VERV) has a market cap of $485M as of May 01, 2025.
What is the P/E ratio for Verve Therapeutics stock?
The price to earnings (P/E) ratio for Verve Therapeutics (VERV) stock is 0 as of May 01, 2025.
Does Verve Therapeutics stock pay dividends?
No, Verve Therapeutics (VERV) stock does not pay dividends to its shareholders as of May 01, 2025.
When is the next Verve Therapeutics dividend payment date?
Verve Therapeutics (VERV) stock does not pay dividends to its shareholders.
What is the beta indicator for Verve Therapeutics?
Verve Therapeutics (VERV) has a beta rating of 1.78. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.